Detalles de la búsqueda
1.
Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study.
Pathologica
; 114(4): 278-287, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36083243
2.
The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050.
Future Oncol
; 17(7): 783-794, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33164569
3.
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Oncologist
; 24(6): e327-e337, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30796151
4.
Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer.
Future Oncol
; 15(24): 2795-2805, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31313942
5.
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 18(11): 1454-1466, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28958502
6.
Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion.
Curr Oncol
; 30(11): 10033-10042, 2023 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37999149
7.
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients.
Crit Rev Oncol Hematol
; 169: 103536, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34801697
8.
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2).
J Thorac Oncol
; 17(12): 1404-1414, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36096442
9.
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.
J Hematol Oncol
; 15(1): 9, 2022 01 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35062993
10.
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
Lung Cancer
; 152: 127-134, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33387727
11.
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Drugs
; 81(2): 257-266, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33331989
12.
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
Thorac Cancer
; 12(6): 880-889, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33527756
13.
[Target therapies in translocated ALK lung cancer: treatment management in oncology center of Lazio.] / Target therapies nel tumore al polmone ALK-positivo: gestione del trattamento nei centri di oncologia del LazioIncontro di approfondimento e confronto sulla gestione dei pazienti e sulla strategia terapeutica nei carcinomi polmonari positivi al riarrangiamento di ALK.
Recenti Prog Med
; 111(12): 63e-69e, 2020 12.
Artículo
en Italiano
| MEDLINE | ID: mdl-33362185
14.
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
Eur J Cancer
; 128: 17-26, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32109847
15.
Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
Lung Cancer
; 140: 71-79, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31884129
16.
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
Eur J Cancer
; 130: 155-167, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32220780
17.
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.
Oncoimmunology
; 9(1): 1710389, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32002308
18.
Prophylactic Dermatologic Treatment of Afatinib-Induced Skin Toxicities in Patients with Metastatic Lung Cancer: A Pilot Study.
Scientifica (Cairo)
; 2019: 9136249, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30838155
19.
Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: recommendations for clinical practice.
Expert Rev Respir Med
; 13(3): 217-228, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30640563
20.
Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases.
Anticancer Res
; 39(8): 4265-4271, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31366516